417 related articles for article (PubMed ID: 29393911)
21. Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer.
Surlin V; Ioana M; Pleşea IE
Rom J Morphol Embryol; 2011; 52(1 Suppl):231-6. PubMed ID: 21424059
[TBL] [Abstract][Full Text] [Related]
22. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage.
Davidson RK; Waters JG; Kevorkian L; Darrah C; Cooper A; Donell ST; Clark IM
Arthritis Res Ther; 2006; 8(4):R124. PubMed ID: 16859525
[TBL] [Abstract][Full Text] [Related]
23. Stiffness post-total knee replacement: A proof of principle study investigating the effect of gene expression analysis of markers of fibrosis.
Mann CJ; Bradley AM; Jones ER; McNamara IR; Smith TO; Riley GP
Knee; 2019 Aug; 26(4):914-922. PubMed ID: 31174979
[TBL] [Abstract][Full Text] [Related]
24. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma.
Zhang M; Zhu GY; Gao HY; Zhao SP; Xue Y
J Surg Oncol; 2011 Mar; 103(3):243-7. PubMed ID: 21337552
[TBL] [Abstract][Full Text] [Related]
25. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors.
Nagase H; Brew K
Biochem Soc Symp; 2003; (70):201-12. PubMed ID: 14587293
[TBL] [Abstract][Full Text] [Related]
26. The Role of Tissue Inhibitors of Metalloproteinases in Organ Development and Regulation of ADAMTS Family Metalloproteinases in
Kubota Y; Nishiwaki K; Ito M; Sugimoto A
Genetics; 2019 Jun; 212(2):523-535. PubMed ID: 30992386
[TBL] [Abstract][Full Text] [Related]
27. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
28. Spatio-temporal expression profile of matrix metalloproteinase (Mmp) modulators Reck and Sparc during the rat ovarian dynamics.
Levin G; Coelho TM; Nóbrega NG; Trombetta-Lima M; Sogayar MC; Carreira ACO
Reprod Biol Endocrinol; 2018 Nov; 16(1):116. PubMed ID: 30424792
[TBL] [Abstract][Full Text] [Related]
29. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
30. The expression and localization of selected matrix metalloproteinases (MMP-2, -7 and -9) and their tissue inhibitors (TIMP-2 and -3) in follicular cysts of sows.
Grzesiak M; Kaminska K; Knapczyk-Stwora K; Hrabia A
Theriogenology; 2022 Jun; 185():109-120. PubMed ID: 35395587
[TBL] [Abstract][Full Text] [Related]
31. Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure.
Pogge von Strandmann E; Reinartz S; Wager U; Müller R
Trends Cancer; 2017 Feb; 3(2):137-148. PubMed ID: 28718444
[TBL] [Abstract][Full Text] [Related]
32. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium.
Goffin F; Munaut C; Frankenne F; Perrier D'Hauterive S; Béliard A; Fridman V; Nervo P; Colige A; Foidart JM
Biol Reprod; 2003 Sep; 69(3):976-84. PubMed ID: 12773401
[TBL] [Abstract][Full Text] [Related]
33. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Stokes A; Joutsa J; Ala-Aho R; Pitchers M; Pennington CJ; Martin C; Premachandra DJ; Okada Y; Peltonen J; Grénman R; James HA; Edwards DR; Kähäri VM
Clin Cancer Res; 2010 Apr; 16(7):2022-35. PubMed ID: 20305301
[TBL] [Abstract][Full Text] [Related]
34. [The role of matrixmetalloproteinases in the tumor growth and metastasis].
Velinov N; Poptodorov G; Gabrovski N; Gabrovski S
Khirurgiia (Sofiia); 2010; (1):44-9. PubMed ID: 21972705
[TBL] [Abstract][Full Text] [Related]
35. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease.
Johnston P; Chojnowski AJ; Davidson RK; Riley GP; Donell ST; Clark IM
J Hand Surg Am; 2007 Mar; 32(3):343-51. PubMed ID: 17336841
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of leptin on ovarian metalloproteinases and their tissue inhibitors between in vivo and in vitro studies.
Bilbao MG; Di Yorio MP; Faletti AG
J Endocrinol; 2011 Apr; 209(1):65-74. PubMed ID: 21220407
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.
Giantin M; Aresu L; Benali S; Aricò A; Morello EM; Martano M; Vascellari M; Castagnaro M; Lopparelli RM; Zancanella V; Granato A; Mutinelli F; Dacasto M
J Comp Pathol; 2012 Nov; 147(4):419-29. PubMed ID: 22520817
[TBL] [Abstract][Full Text] [Related]
38. Tissue inhibitor of metalloproteinases-4. The road less traveled.
Melendez-Zajgla J; Del Pozo L; Ceballos G; Maldonado V
Mol Cancer; 2008 Nov; 7():85. PubMed ID: 19025595
[TBL] [Abstract][Full Text] [Related]
39. Extracellular matrix remodeling and inflammatory pathway in human endometrium: insights from uterine leiomyomas.
Governini L; Marrocco C; Semplici B; Pavone V; Belmonte G; Luisi S; Petraglia F; Luddi A; Piomboni P
Fertil Steril; 2021 Nov; 116(5):1404-1414. PubMed ID: 34256950
[TBL] [Abstract][Full Text] [Related]
40. Matrix Metalloproteinases: How Much Can They Do?
Ågren MS; Auf dem Keller U
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
